![](/images/graphics-bg.png)
Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase III Report
المؤلفون المشاركون
Han, Wei-Dong
Fan, Hui
Lu, Xuechun
Wang, Xiaohui
Liu, Yang
Guo, Bo
Zhang, Yan
Zhang, Wenying
Nie, Jing
Feng, Kaichao
Chen, Meixia
Zhang, Yajing
Wang, Yao
Shi, Fengxia
Fu, Xiaobing
Zhu, Hongli
المصدر
Journal of Immunology Research
العدد
المجلد 2014، العدد 2014 (31 ديسمبر/كانون الأول 2014)، ص ص. 1-14، 14ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2014-05-20
دولة النشر
مصر
عدد الصفحات
14
التخصصات الرئيسية
الملخص EN
Aberrant DNA methylation is one of the main drivers of tumor initiation and progression.
The reversibility of methylation modulation makes it an attractive target for novel anticancer therapies.
Clinical studies have demonstrated that high-dose decitabine, a hypomethylating agent, results in some clinical benefits in patients with refractory advanced tumors; however, they are extremely toxic.
Low doses of decitabine minimize toxicity while potentially improving the targeted effects of DNA hypomethylation.
Based on these mechanisms, low-dose decitabine combined with chemoimmunotherapy may be a new treatment option for patients with refractory advanced tumors.
We proposed the regimen of low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors.
A favorable adverse event profile was observed in our trial that was highlighted by the finding that most of these adverse events were grades 1-2.
Besides, the activity of our cohort was optimistic and the clinical benefit rate was up to 60%, and the median PFS was prolonged compared with PFS to previous treatment.
We also identified a significant correlation between the PFS to previous treatment and clinical response.
The low-dose DAC decitabine-based chemoimmunotherapy might be a promising protocol for improving the specificity and efficiency of patients with refractory advanced solid tumors.
This trial is registered in the ClinicalTrials.gov database (identifier NCT01799083).
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Fan, Hui& Lu, Xuechun& Wang, Xiaohui& Liu, Yang& Guo, Bo& Zhang, Yan…[et al.]. 2014. Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase III Report. Journal of Immunology Research،Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-1040852
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Fan, Hui…[et al.]. Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase III Report. Journal of Immunology Research No. 2014 (2014), pp.1-14.
https://search.emarefa.net/detail/BIM-1040852
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Fan, Hui& Lu, Xuechun& Wang, Xiaohui& Liu, Yang& Guo, Bo& Zhang, Yan…[et al.]. Low-Dose Decitabine-Based Chemoimmunotherapy for Patients with Refractory Advanced Solid Tumors: A Phase III Report. Journal of Immunology Research. 2014. Vol. 2014, no. 2014, pp.1-14.
https://search.emarefa.net/detail/BIM-1040852
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-1040852
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)